Share on LinkedInShare on LinkedIn

VIDEO · 06 OCTOBER 2025

Class Actions In Canada: At The Forefront Of Pharma Litigation (Video)

Fasken
Explore more from Fasken

The latest video from our Class Action Litigation group breaks down key procedural contrasts, new legislative risks, and creative defence strategies shaping pharma litigation in Canada today.

CanadaLitigation, Mediation & Arbitration
Andrew Borrell
Andrew Borrell
Zohaib Maladwala
Zohaib Maladwala
Mirna Kaddis
Mirna Kaddis
Author LinkedIn connections

What makes pharma class actions in Canada so different from the U.S.?

The latest video from our Class Action Litigation group breaks down key procedural contrasts, new legislative risks, and creative defence strategies shaping pharma litigation in Canada today. From certification battles to government-led actions, we explore what's changing—and what companies need to watch.

self

Need legal advice?

We approach class action litigation with one goal: to win, either in court or through strategically negotiated settlements. We have an experienced legal team that can advocate for you, develop a strong tactical response, and help you navigate the Canadian maze.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Read more about

Related Comparative Guides

See more popular content from

Article

Court Of Appeal Reaffirms The Limited Role Of The Courts In Charter Claims

In Cycle Toronto v Ontario (Attorney General), 2026 ONCA 582, the Ontario Court of Appeal overturned a lower court ruling preventing the government of Ontario from ripping out 19 kilometers of protected bike lines along three major Toronto roadways. The decision underlines the limited role of the courts in reviewing policy-based government decisions.
CanadaLitigation, Mediation & Arbitration
Singleton Urquhart Reynolds Vogel LLP
Singleton Urquhart Reynolds Vogel LLP
Article

Spoliation: What Litigants Need To Know About Preserving Evidence

The Supreme Court of Canada has clarified the legal test for spoliation, establishing a four-part framework that litigants must understand when preserving evidence. This doctrine, rooted in ancient Roman law, creates a mandatory presumption against parties who intentionally destroy or suppress relevant evidence, with courts now empowered to impose severe but proportionate remedies based on the magnitude of the misconduct.
CanadaLitigation, Mediation & Arbitration
Alexander Holburn Beaudin + Lang LLP
Alexander Holburn Beaudin + Lang LLP
Article

Do Canadian Manufacturers Owe A Duty To Develop Safer Alternatives?

The British Columbia Court of Appeal has left open the possibility that pharmaceutical manufacturers may owe a duty of care to develop safer alternatives to their existing products, even when those products are properly approved and labeled. This decision in Gilead Sciences, Inc. v. I.F. contrasts sharply with a recent California Supreme Court ruling that rejected such a "duty to innovate," potentially setting Canada on a divergent path in product liability law.
CanadaLitigation, Mediation & Arbitration
Torys
Torys
Article

The Coldcard Exploit: Why Victims May Have Two Routes To Recovery

A five-year-old firmware defect in Coldcard hardware wallets has enabled attackers to systematically drain an estimated $116 million in Bitcoin from over 5,200 victims since July 2026. This unprecedented exploit raises critical questions about manufacturer liability and creates two distinct legal pathways for recovery: blockchain tracing against the perpetrators and potential litigation against Canadian manufacturer Coinkite for product defects that undermined the fundamental security promise of devices mar
CanadaLitigation, Mediation & Arbitration
WeirFoulds LLP
WeirFoulds LLP
Article

Court Of Appeal Summaries (May 25 – 29, 2026)

The Court of Appeal for Ontario issued several significant rulings during the week of May 25, 2026, addressing critical issues spanning professional regulation, defamation law, negligence liability, and commercial disputes. These decisions clarify important legal principles regarding costs awards against regulatory bodies, anti-SLAPP motion analysis, occupiers' duties to warn of hidden dangers, and enforcement of settlement agreements in various contexts.
CanadaLitigation, Mediation & Arbitration
Blaney McMurtry LLP
Blaney McMurtry LLP
Article

Canada’s Counter-Tariffs On US Goods: A Primer On What Canadian Businesses Need To Know

Effective September 8, 2026, Canada implemented retaliatory tariffs on certain U.S. goods in response to the initial 50% tariffs imposed by the US under Section 338 of the Tariff Act of 1930. To operationalize these measures, the Canada Border Services Agency (CBSA) issued Customs Notice 26-23, establishing binding administrative rules on how the surtax will be applied, calculated, and collected.
CanadaInternational Law
Fasken
Fasken
Article

Counter-Tariffs In Force, U.S. Import Bans Announced, A Cabinet Planning Forum, An Investment Summit, EU Diplomatic Overtures And A House Returning

With Labour Day now behind us, Parliament Hill is gearing up for its September 21 return. Canada’s counter-tariffs on nearly $28 billion in American goods are now in force, and the United States has already escalated in response: President Trump has signed measures to ban certain Canadian alcohol, dairy-related products, molasses, non-alcoholic beer, motorcycles and mopeds from entering the U.S. market as of September 29, while modifying the list of Canadian goods subject to 50% tariffs effective September 15 and directing action to remove Canadian-origin products from U.S. government procurement schedules.
CanadaInternational Law
Fasken
Fasken
Article

More Than Skin Deep: Ontario Considers A Makeover Of Cosmetic Injection Rules

A regulatory shift now under consideration in Ontario could reshape how the province’s medical aesthetic clinics operate. The proposal, which would change how nurses are authorized to administer medical aesthetic services, invites a broader look at how Ontario currently regulates cosmetic injections and how the proposed changes would align the province more closely with the regulatory frameworks already in place elsewhere in Canada. While these procedures are often marketed as routine “spa” services, they remain medical acts that involve prescription products and carry clinical risks.
CanadaFood, Drugs, Healthcare, Life Sciences
Fasken
Fasken